SURV
Survodutide
A synthetic acylated peptide and an agonist at two receptors: the glucagon receptor and the GLP-1 receptor. The pairing is different from the dual GIP/GLP-1 agonists in the same category here — glucagon rather than GIP is the second target.
Survodutide has 23 registered human studies on ClinicalTrials.gov, reaching phase 3, covering 12,628 planned or enrolled participants across the 23 studies that published a figure. No FDA-approved product contains Survodutide. 69 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names Survodutide; the registry search is fuzzy, so every match is re-checked. None of this says whether Survodutide works or is safe.
FDA status
Research only
Human studies
23
Furthest phase
Phase 3
Papers, 10 yr
69
Readership
1,155
monthly average, Feb–Jul 2026
Tracking since 2026-07-29 · About this data
What has actually been tested in humans
Reached phase 3 or 4, not approved
23
Registered human studies
Phase 3
Furthest phase reached
12,628
Planned or enrolled participants, across 23 studies that published a figure
None
No FDA-approved product contains it
24 loose registry matches were checked and 23 confirmed — 1 named something else and were discarded. We count a study only when Survodutide is named as an intervention in it.
Registered means registered — not that the study finished, and not that it found anything. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What Survodutide is, and what it has been studied for
Survodutide is classified by ChEMBL as a protein, and appears in trial registrations under BI 456906 and BI-456906. Its FDA substance identifier is 2ALA66NS64.
Across 23 registered trials, it has been studied in Obesity, Healthy, Overweight and Non-Alcoholic SteatoHepatitis (NASH). A condition here is what a sponsor registered the trial under — it records what was investigated, not what was shown.
The trials were run by Boehringer Ingelheim and University Medical Center Groningen. A named commercial sponsor means a compound is in formal development; its absence does not mean the opposite, only that no company has registered a trial under its own name.
How far it got
Survodutide reached Phase 3 across 23 registered trials.
No FDA-approved product contains Survodutide. A compound can stop at any rung for commercial reasons as easily as scientific ones, and the registry does not record which.
Is anyone studying Survodutide?
Papers published each year that name Survodutide in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 0 | 0 | Yes |
| 2018 | 0 | 0 | Yes |
| 2019 | 0 | 0 | Yes |
| 2020 | 0 | 0 | Yes |
| 2021 | 0 | 2 | Yes |
| 2022 | 0 | 1 | Yes |
| 2023 | 2 | 4 | Yes |
| 2024 | 21 | 10 | Yes |
| 2025 | 35 | 4 | Yes |
| 2026 | 25 | 2 | No |
69 papers and 23 registered trials between 2017 and 2026. A paper counts when “Survodutide” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on Survodutide
69 indexed papers name Survodutide in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
- Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
- Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
- Emerging pharmacotherapies for obesity: A systematic review
- Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
- Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis
- Weight management treatment in obesity
- The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation
Collected 2026-08-02from PubMed, phrase-matched on “Survodutide” in title and abstract. Run the same search.
About Survodutide
A synthetic acylated peptide and an agonist at two receptors: the glucagon receptor and the GLP-1 receptor. The pairing is different from the dual GIP/GLP-1 agonists in the same category here — glucagon rather than GIP is the second target.
- Also known as
- BI 456906
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Reading on this compound
All articles →PepRack articles that reference this compound. This is not a news feed — we syndicate nothing and publish no datelines.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.